RTI Surgical® Continues to Advance Science Behind Allograft Implantation

July 25, 2016


ALACHUA, Fla.–(BUSINESS WIRE)–RTI Surgical, Inc. (RTI) (Nasdaq: RTIX), a leading global surgical implant company, announced that a peer-reviewed, pre-clinical study titled Multipotent adult progenitor cells on an allograft scaffold facilitate the bone repair processhas been published in the latest edition of the Journal of Tissue Engineering.

The pre-clinical study, conducted by Amanda LoGuidice, PhD., used similar materials to the proprietary, patented MAPC®-based technology used in RTI Surgical’s map3® Cellular Allogeneic Bone Grafts. The study is the first peer-reviewed, published pre-clinical study comparing multipotent adult progenitor cells (MAPCs) to mesenchymal stem cells (MSCs) in bone healing.

Results demonstrated MAPCs exhibited a more robust angiogenic protein release profile compared to MSCs in vitro. In addition, MAPCs demonstrated enhanced revascularization and new bone formation in vivo in an orthotopic defect model when compared to MSCs when placed on a DBM scaffold.

“We value research that helps us continue to provide surgeons with safe, high-quality implants,” said Carrie A. Hartill, executive vice president and chief scientific officer of RTI Surgical. “We are proud of our advancements in the allograft industry and this study’s results that support the science behind our map3 implant.”

The full study can be viewed here.

About RTI Surgical Inc.

RTI Surgical is a leading global surgical implant company providing surgeons with safe biologic, metal and synthetic implants. Committed to delivering a higher standard, RTI’s implants are used in sports medicine, general surgery, spine, orthopedic, trauma and cardiothoracic procedures and are distributed in nearly 50 countries. RTI is headquartered in Alachua, Fla., and has four manufacturing facilities throughout the U.S. and Europe. RTI is accredited in the U.S. by the American Association of Tissue Banks and is a member of AdvaMed. For more information, please visit

MAPC® is a registered trademark of Athersys, Inc.

Forward Looking Statement

This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management’s current expectations, estimates and projections about our industry, our management’s beliefs and certain assumptions made by our management. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” variations of such words and similar expressions are intended to identify such forward-looking statements. In addition, except for historical information, any statements made in this communication about anticipated financial results, growth rates, new product introductions, future operational improvements and results or regulatory actions or approvals or changes to agreements with distributors also are forward-looking statements. These statements are not guarantees of future performance and are subject to risks and uncertainties, including the risks described in public filings with the U.S. Securities and Exchange Commission (SEC). Our actual results may differ materially from the anticipated results reflected in these forward-looking statements. Copies of the company’s SEC filings may be obtained by contacting the company or the SEC or by visiting RTI’s website at or the SEC’s website at


RTI Surgical, Inc.
Wendy Crites Wacker, APR, 386-418-8888
Vice President, Global Communications


Josh Sandberg

Josh Sandberg is the President and CEO of Ortho Spine Partners and sits on several company and industry related Boards. He also is the Creator and Editor of OrthoSpineNews.

Related Articles

Back to top button